Detailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing Multiple Sclerosis Presented at ECTRIMS
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: GlobeNewswire
Company Announcement Details from the ASCLEPIOS I & II studies of subcutaneous ofatumumab (OMB157) versus teriflunomide in patients with relapsing multiple sclerosis (RMS) were presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Copenhagen, Denmark; September 13, 2019 – Genmab A/S (Nasdaq: GMAB) announced that its partner for ofatumumab, Novartis, presented positive results from the Phase III ASCLEPIOS I and II studies at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), in Stockholm, Sweden. The head-to-head ASCLEPIOS studies investigated the efficacy and safety of monthly subcutaneous ofatumumab 20mg versus once daily oral teriflunomide 14mg in adults with relapsing forms of multiple sclerosis (RMS) with the primary endpoints of reduction in the number of confirmed relapses, evaluated as the annualized relapse rate (ARR). Both ASCLEPIOS I and II studies met their p
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- BioNJ Unveils "Time Off for Clinical Trials" Initiative [Yahoo! Finance]Yahoo! Finance
- Genmab A/S (NASDAQ: GMAB) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $48.00 price target on the stock, up previously from $46.00.MarketBeat
- High Growth Tech Stocks To Watch In November 2024 [Yahoo! Finance]Yahoo! Finance
- Genmab Announces Financial Results for the First Nine Months of 2024 [Yahoo! Finance]Yahoo! Finance
- Genmab Announces Financial Results for the First Nine Months of 2024GlobeNewswire